About the ABPI

The ABPI represents innovative resea​rch-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.

Globally our industry is researching and developing more than 7,000 new medicines.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.​​​​​​​

References:

[i] Under current data protection legislation it is possible for individuals to query data shown against their name and withdraw consent to publish this data for the three years that it is in the public domain. Companies are also able to amend data where relevant during this period. RAND Europe analysed a data snapshot from 19 January 2017 compared to the data snapshot at launch 30 June 2016.

[ii]

  • The majority of companies appear to have completed the HCP aggregate data rows and columns by assuming the percentage cell for each column of category of spend was a percentage of the total number of individuals in aggregate and disaggregate for this type of spend. 

  • Fewer companies appear to have completed the HCP aggregate data rows and columns by assuming the percentage cell for each column of category of spend was a percentage of the total number of individuals in both aggregate and disaggregate across all types of spend.

  • Even fewer companies provided aggregate data in a different way to those outlined above​​.

Media enquiries


+44 (0) 20 7747 7147​​